2009 Summary Compensation Table
Name and Principal Position
(a)

Year
(b)

Option Awards
($)
(f)

Non-Equity
Incentive Plan
Compensation
($)
(g)

Change in
Pension Value and
Non-Qualified Deferred
Compensation
Earnings
($)
(h)

All Other
Compensation
($)
(i)

Total
($)
(j)

J. Kindler
Chairman and
Chief Executive Officer
     

2009

2008
2007

2,575,250

2,222,026
3,123,600

3,500,000

3,000,000
—

1,238,772

759,298
477,783

449,731

438,261
441,456

14,898,038

15,547,600
13,075,099

F. D’Amelio
Chief Financial Officer
     
     

2009

2008
2007

1,204,478

938,189
1,311,080

1,420,000

1,250,000
—

465,428

423,085
927,990

204,697

127,303
32,278

7,858,969

6,979,111
12,338,821

I. Read
Group President, Worldwide Biopharmaceutical Businesses
     

2009

2008
2007

1,154,478

938,189
1,139,750

1,657,000

1,250,000
—

1,915,639

963,274
133,784

226,053

237,188
160,626

9,447,036

7,629,185
4,560,869

M. Mackay
President,
Pharmatherapeutics Research & Development

2009

2008
2007

791,420

888,810
781,325

1,025,000

1,030,000
—

628,620

418,645
113,687

204,951

97,441
115,217

5,878,806

6,718,580
3,590,158

F. Lewis-Hall
Chief
Medical Officer

2009

—

—

65,195

1,892,335

5,087,263